NTRA Stock Overview
A diagnostics company, develops and commercializes molecular testing services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Natera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$162.31 |
| 52 Week High | US$183.00 |
| 52 Week Low | US$70.71 |
| Beta | 1.65 |
| 1 Month Change | -3.16% |
| 3 Month Change | -1.27% |
| 1 Year Change | 130.36% |
| 3 Year Change | 142.47% |
| 5 Year Change | 328.20% |
| Change since IPO | 613.76% |
Recent News & Updates
Recent updates
Natera: Poised For A Great Future But I'd Wait For A Pullback
Dec 31Is Natera (NASDAQ:NTRA) Weighed On By Its Debt Load?
Dec 30
Subdued Growth No Barrier To Natera, Inc. (NASDAQ:NTRA) With Shares Advancing 25%
Nov 19Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$158
Nov 15Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
Oct 31Natera, Inc.'s (NASDAQ:NTRA) Intrinsic Value Is Potentially 20% Below Its Share Price
Sep 18Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?
Jul 05Natera: Overdue For A Breather
Jun 03Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119
May 12Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?
Mar 30Natera: Capitalizing On The Positive Momentum Of Personalized Medicine
Mar 22Is Natera (NASDAQ:NTRA) A Risky Investment?
Mar 03Shareholder Returns
| NTRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.4% | 2.2% | -2.2% |
| 1Y | 130.4% | -1.9% | 18.3% |
Return vs Industry: NTRA exceeded the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: NTRA exceeded the US Market which returned 18.3% over the past year.
Price Volatility
| NTRA volatility | |
|---|---|
| NTRA Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NTRA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NTRA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 3,288 | Steve Chapman | www.natera.com |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.
Natera, Inc. Fundamentals Summary
| NTRA fundamental statistics | |
|---|---|
| Market cap | US$21.43b |
| Earnings (TTM) | -US$214.69m |
| Revenue (TTM) | US$1.53b |
14.0x
P/S Ratio-99.8x
P/E RatioIs NTRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTRA income statement (TTM) | |
|---|---|
| Revenue | US$1.53b |
| Cost of Revenue | US$648.58m |
| Gross Profit | US$883.38m |
| Other Expenses | US$1.10b |
| Earnings | -US$214.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 57.66% |
| Net Profit Margin | -14.01% |
| Debt/Equity Ratio | 41.8% |
How did NTRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/23 07:02 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Natera, Inc. is covered by 28 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Raymond Myers | Benchmark Company |